AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2009
Feb 2, 2009
33882_dirs_2009-02-02_a027920e-ce37-4e28-9236-9bb63155f5de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2008-08-21
Reporting Person: Clendeninn Neil James (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2008-08-21 | stock option (right to buy) | $3.889 | A | 2395 | Acquired | 2011-09-16 | Common Stock (2395) | Direct |
| 2008-08-21 | Stock option (right to buy) | $3.889 | A | 952 | Acquired | 2011-12-20 | Common (952) | Direct |
| 2008-08-21 | Stock option (right to buy) | $4.1051 | A | 3702 | Acquired | 2012-08-08 | Common Stock (3702) | Direct |
| 2008-08-21 | Stock option (right to buy) | $4.1051 | A | 513 | Acquired | 2013-03-23 | Common Stock (513) | Direct |
| 2008-08-21 | Stock option (right to buy) | $18.9263 | A | 3048 | Acquired | 2014-06-28 | Common stock (3048) | Direct |
Footnotes
F1: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0025
F2: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 2.
F3: Received in exchange for a stock option to acquire 11,000 shares of OncoGenex Technologies Inc. ("OncoGenex Technologies") common stock for CAD$0.90 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex Pharmaceuticals, Inc. (the "Arrangement").
F4: Received in the Arrangement in exchange for a stock option to acquire 4,375 shares of OncoGenex Technologies common stock for CAD$0.90 per share.
F5: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0026.
F6: Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 3.
F7: Received in the Arrangement in exchange for a stock option to acquire 17,000 shares of OncoGenex Technologies common stock for CAD$0.95 per share.
F8: Received in the Arrangement in exchange for a stock option to acquire 2,359 shares of OncoGenex Technologies common stock for CAD$0.95 per share.
F9: Due to an administrative error, the original Form 4 overstated the exercise price by $0.0121.
F10: Received in the Arrangement in exchange for a stock option to acquire 14,000 shares of OncoGenex Technologies common stock for CAD$4.38 per share.